NEW YORK–(BUSINESS WIRE)–#ChildhoodCancerAwareness—Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial matching, announces today its newly developed “Hub” aimed to build strategic partnerships with some of the most prominent Just-In-Time (JIT) vendors and provider clinical research teams, looking to facilitate the largest JIT oncology clinical trial network in the world. These vendors and Massive Bio will join forces to provide combined accelerated oncology enrollment solutions and to optimize workflow efficiencies for global pharmaceutical companies.
“We understand the current unmet need to bring trials to cancer patients, develop turnkey solutions to enable community-based sites running rapidly to enroll patients, and making this process efficient and at a global scale. We have been working in ‘stealth mode’ over several months to understand the pros-and-cons of leveraging JIT networks. This analysis resulted in Massive Bio’s “Hub” development, and its key role in managing a series of JIT Oncology Clinical Trial Networks. This first-in-class Hub is responsible for evaluating market players in the JIT arena, understanding the needs of pharmaceutical companies, and Contract Research Organizations (CROs), assessing the provider networks interested in opening JIT sites, and further enabling clinical research services to perform the highest patient enrollment potential”, said Selin Kurnaz, PhD., Co-founder and CEO of Massive Bio. She also added, “We are predominantly looking for strategic partnerships and assessing key targets for acquisition. We already have a half dozen JIT vendors and provider networks interested in partnering with the Hub. We will be announcing major partnerships in the next couple of months. Beyond being a healthcare informatics company, we are the catalyzers and connectors of an entire oncology clinical research service industry, to accelerate drug development and increase efficiency, which is currently a very broken system.”
The newly announced global partnership network will combine Massive Bio’s best-in-class advanced technology, oncology expertise and patient engagement, along with newly developed capabilities from strategic industry-leading JIT services, to form the world’s largest AI-enabled oncology site network, accentuated by accelerated patient enrollment services – all delivered under a results-based contracting model that offers cost and time certainty in trial delivery. Massive Bio has an enrollment rate that is 4x higher than any leading precision oncology platform due to its dedicated focus on oncology, superior technology, sub-specialist supervision combined by clinical navigation support and outcomes collection.
“Massive Bio is excited to start this collaboration to further accelerate oncology research and clinical trials”, said Cagatay Culcuoglu, Co-founder and CTO of Massive Bio. In addition, he has added that “Our newly developed capabilities include our SYNERGY-AI platform, and a community of US-based oncology research sites, all pre-contracted, pre-qualified, and ready for rapid activation into a trial. Massive Bio’s expertise in precision oncology, AI-powered patient identification and patient engagement, combined with JIT solutions are ideal to reducing operational barriers in clinical trial enrollment at the point of care.”
Massive Bio’s Co-founder and Chief Medical Advisor, Arturo Loaiza-Bonilla, MD, MSEd, mentions that, “This important announcement is another milestone to our overarching goal of improving access to clinical trials for every patient, everywhere. This partnership network offers an unprecedented opportunity to activating our AI enabled precision oncology expertise and patient-centered perspective at a global scale, just where the patient needs it the most, while advancing cancer research.” He also added, “Massive Bio services pre-identified patients in your practice so that you no longer need to comb your database, ask for referrals, screen charts and keep track of all the inclusion and exclusion criteria of every study. Our partners’ JIT capabilities jumpstart oncology trial enrollment and deliver the first patient faster, then continue to find patients to accelerate overall timelines. We will continue partnering with innovative enterprises that are entrusted with the world’s most important research companies, and together we look forward to delivering significant value to the oncology clinical trial space.”
Kurnaz concluded, “With our in-depth industry experience and breadth of solutions, we are uniquely equipped to helping pharmaceutical and biotech clients quickly enroll patients and maintain extremely high retention rates. Massive Bio is a young company working relentlessly to create new partnerships and continue its unwavering commitment to creating a world without cancer. This newly announced collaborative strategy is just one of many ways we are reaching our goals as we support cancer patients all over the world. We invite all stakeholders to collaborate with Massive Bio and join us in making a major difference in the fight for cancer globally”.
About Massive Bio:
Massive Bio connects patients and their treating oncologist to the best available clinical trials and advanced care options while enabling enterprises to get access to patients at community practices to enhance oncology research. Massive Bio provides clinical trial services (patient identification, pre-screening, site selection) and real-world evidence services to Contract Research Organizations (CROs), pharmaceutical companies, and providers. Massive Bio sits at the intersection of patient acquisition, Artificial Intelligence (AI) based scalable pre-screening, operationalization support and real-world data to connect patients to oncology trials. It was established in 2014, headquartered in New York, and has a dedicated patient contact, provider support and clinical research center in Newtown, Pennsylvania. For more information, visit www.massivebio.com.
Selin Kurnaz PhD.
Co-Founder and CEO of Massive Bio